Gut-Brain Axis / Inflammasome Programs

About InveniAI

InveniAI is a private, pre-revenue biotechnology company founded in 2017 and headquartered in Guilford, Connecticut. It operates as an AI/ML platform company, partnering with pharmaceutical and biotech firms to accelerate the identification and validation of novel drug candidates. The company has established several strategic collaborations with industry players like Kyowa Kirin and Shionogi, indicating validation of its technology. Its business model centers on leveraging its AlphaMeld® platform to build a pipeline of partnered and internal programs, primarily targeting chronic inflammatory diseases of the gut.

Therapeutic Areas